1
|
Bi Y, Ren J, Han X. Clinical Outcomes of Drug-eluting Beads Transarterial Chemoembolization for Unresectable Gastric Carcinoma. J Gastrointest Surg 2023; 27:2577-2579. [PMID: 37407896 DOI: 10.1007/s11605-023-05738-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Accepted: 06/03/2023] [Indexed: 07/07/2023]
Affiliation(s)
- Yonghua Bi
- Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, 450052, China
| | - Jianzhuang Ren
- Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, 450052, China
| | - Xinwei Han
- Department of Interventional Radiology, First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, 450052, China.
| |
Collapse
|
2
|
Bi Y, Li F, Ren J, Han X. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer. Front Pharmacol 2022; 13:1079707. [PMID: 36518678 PMCID: PMC9742261 DOI: 10.3389/fphar.2022.1079707] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Accepted: 11/17/2022] [Indexed: 08/22/2023] Open
Abstract
Aim: Drug-eluting beads are usually applied for the treatment of advanced hepatocellular carcinoma. Oxaliplatin was suggested as first-line therapy for advanced non-small-cell lung cancer. However, there has been little investigation about the application of drug-eluting beads transarterial chemoembolization (DEB-TACE) with oxaliplatin-loaded CalliSpheres beads (CB) for the treatment of unresectable or advanced lung cancer. We aimed to investigate the safety and efficacy of oxaliplatin-loaded DEB-TACE for the treatment of unresectable or advanced lung cancer. Methods: From January 2019 to December 2021, all patients with primary unresectable or advanced lung cancer who underwent DEB-TACE with oxaliplatin-loaded CB were retrospectively enrolled. This study defined overall survival and objective response rate (ORR) as the primary endpoints, disease control rate (DCR) and progression-free survival (PFS) as the secondary endpoints. Results: A total of 33 sessions of DEB-TACE were performed in 20 patients, with a mean of 1.7 ± 1.0 sessions. A total of 55 arteries were emoblized by CB, including 40 bronchial arteries, 13 intercostal arteries, one suprarenal artery and one inferior phrenical artery. No procedural-related mortality or severe complications were observed. The median tumor diameter was 49.0 [Interquartile range (IQR) 37.8-66.8] mm before DEB-TACE, and decreased to 38.8 (IQR 27.7-56.9), 26.1 (IQR 19.1-48.8), and 20.5 (IQR 13.1-49.7) mm at 1, 3 and 6 months later (p = 0.04). The ORR and DCR at 1, 3, and 6 months after DEB-TACE were 28.6% and 92.9%, 38.5% and 84.6%, 30.8% and 61.5%, respectively. The median PFS and median overall survival was 9.9 and 29.6 months, respectively. Conclusion: DEB-TACE with oxaliplatin-loaded CB is suggested as a safe, effective and well-tolerated treatment for patients with unresectable or advanced lung cancer.
Collapse
Affiliation(s)
- Yonghua Bi
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Fazhong Li
- Department of Interventional Radiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, China
| | - Jianzhuang Ren
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Xinwei Han
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| |
Collapse
|
3
|
Shi Q, Lu Y, Huang S, Zhou C, Yang C, Liu J, Ma J, Xiong B. Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization in vitro, pharmacokinetics and tumor response in vivo. Drug Deliv 2021; 27:1301-1307. [PMID: 32924634 PMCID: PMC7534301 DOI: 10.1080/10717544.2020.1818881] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Apatinib mesylate is an oral antiangiogenic agent that can inhibit activation of vascular endothelial growth factor receptor-2 tyrosine kinase. However, its therapeutic use in liver cancer is restricted due to severe systemic toxicity. Our work aimed to construct apatinib-loaded CalliSpheres Beads (CBAPA) and investigate its application in transarterial chemoembolization (TACE) of liver cancer. The established stock solution containing 20, 40 or 60 mg apatinib were fully mixed with 100-300 μm CalliSpheres Beads (CB) for 2 hours, respectively. The highest loading efficiency at 30 min after combination in 20 mg group (maximum 70.7%). Further, apatinib can be steadily released from CBAPA in vitro release test. For pharmacokinetics and tumor response in vivo, sixty New Zealand white rabbits with VX2 liver tumor were assigned into four groups: sham (NS) group, apatinib solution alone (APA) group, CB group and CBAPA group. Apatinib was measured in plasma and liver tissue by high performance liquid chromatography-tandem mass spectrometry. Compared to APA group, the administration of apatinib by TACE with CBAPA resulted in low systemic concentration. In addition, intratumoural apatinib concentration was higher than adjacent hepatic parenchyma in the CBAPA group. Compared to other three groups, CBAPA group achieved lower tumor growth rate and improved survival time. In conclusion, these findings provide a basis for the potential application of apatinib-loaded CalliSpheres Beads in liver cancer.
Collapse
Affiliation(s)
- Qin Shi
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Yongning Lu
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Songjiang Huang
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Chen Zhou
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Chongtu Yang
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Jiacheng Liu
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Jinqiang Ma
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Bin Xiong
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.,Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| |
Collapse
|
4
|
Liu JF, Duan XH, Ren JZ, Jiao DC, Han XW. [Comparative effect of CalliSpheres drug loading microspheres and lipiodol transarterial chemoembolization in the treatment of huge primary liver cancer]. Zhonghua Gan Zang Bing Za Zhi 2019; 27:460-462. [PMID: 31357764 DOI: 10.3760/cma.j.issn.1007-3418.2019.06.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J F Liu
- Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
| | - X H Duan
- Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
| | - J Z Ren
- Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
| | - D C Jiao
- Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
| | - X W Han
- Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China; Intervention and Clinical Research Center of Henan Province, Zhengzhou 450002, China
| |
Collapse
|
5
|
Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019; 18:1533033819830751. [PMID: 30862264 PMCID: PMC6416678 DOI: 10.1177/1533033819830751] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The aim of this study was to compare the treatment response, survival, liver function,
and adverse event incidence of drug-eluting bead transcatheter arterial chemoembolization
using CalliSpheres microspheres with conventional transcatheter arterial chemoembolization
in patients with hepatocellular carcinoma. Seventy-three patients with hepatocellular
carcinoma who received drug-eluting bead transcatheter arterial chemoembolization (using
CalliSpheres microspheres) or conventional transcatheter arterial chemoembolization
treatment were consecutively enrolled. Treatment response was assessed by modified
Response Evaluation Criteria in Solid Tumors at month 1/month 3/month 6; posttreatment,
liver function indexes, and adverse events were recorded. Progression-free survival and
overall survival were also calculated. Objective response rate of patients at months 1, 3,
and 6, disease control rate of patients and objective response rate of nodules at month 3
were increased in drug-eluting bead transcatheter arterial chemoembolization group
compared with conventional transcatheter arterial chemoembolization group. In addition,
drug-eluting bead transcatheter arterial chemoembolization using CalliSpheres microspheres
was an independent factor for predicting better objective response rate at month 1.
Patients in drug-eluting bead transcatheter arterial chemoembolization group achieved
longer progression-free survival and similar overall survival compared to those in
conventional transcatheter arterial chemoembolization group; Cox proportional hazards
regression model analyses revealed that drug-eluting bead transcatheter arterial
chemoembolization using CalliSpheres microspheres was associated with better
progression-free survival while it did not affect overall survival. Meanwhile, most of the
occurrences of abnormal liver function indexes were similar between 2 groups, whereas
drug-eluting bead transcatheter arterial chemoembolization group had a higher percentage
of patients with total bile acid ≥2 upper limit of normal compared to conventional
transcatheter arterial chemoembolization group at month 1. Moreover, the adverse event
incidences between 2 groups were similar. In conclusion, drug-eluting bead transcatheter
arterial chemoembolization using CalliSpheres microspheres achieves better treatment
response and progression-free survival while equal safety compared to conventional
transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Collapse
Affiliation(s)
- Hua Xiang
- 1 Department of Interventional Radiology & Vascular Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
| | - Lin Long
- 1 Department of Interventional Radiology & Vascular Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
| | - Yuanhui Yao
- 1 Department of Interventional Radiology & Vascular Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
| | - Zhiyong Fang
- 1 Department of Interventional Radiology & Vascular Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
| | - Zhiming Zhang
- 1 Department of Interventional Radiology & Vascular Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
| | - Yongjin Zhang
- 1 Department of Interventional Radiology & Vascular Surgery, Hunan Provincial People's Hospital, Changsha, Hunan, China
| |
Collapse
|